Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smiths Medical ASD Inc.

Division of Smiths Group PLC
www.smiths-medical.com

Latest From ViaCord Inc.

Back in Fashion: Discovery Platforms (Certain Kinds, at Least)

After the millennial boom in genome-related financings, platform companies went into hiding, surfacing again a few years later in product costume. But much of that has changed. Platforms are getting fed again-largely because, one step higher on the food chain, buyers have an appetite for them.
BioPharmaceutical Strategy

Succeeding in Heart Failure, Incrementally

Because of the heterogeneity of heart failure patients and causes, new drugs to treat heart failure haven't been a huge area of research or business development. Few heart failure drugs are likely to be blockbusters, and there are very few deals around truly novel targets. Biotech start-ups build on known approaches and innovate incrementally, in this market.
BioPharmaceutical Strategy

Stem Cells: What's the Business Model?

The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.
BioPharmaceutical Strategy

Arteriocyte Inc.

Arteriocyte has proprietary technology for selecting and harvesting combinations of multiple stem cell types that, when injected into the arterial system, generate new blood vessels to revascularize ischemic cardiac tissue. The company is starting out with autologous stem cells from patient's bone marrow. It intends to move quickly into products made from allogeneic cells sourced from umbilical cord blood, thus providing physicians with a standardized, off-the-shelf therapy.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Smiths Group PLC
  • Senior Management
  • Contact Info
  • Smiths Medical ASD Inc.
    9 Riverside Rd.
    Weston, MA 02493
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register